investor.endocyte.com
Investor Relations | Endocyte, Inc.The Investor Relations website contains information about Endocyte, Inc.'s business for stockholders, potential investors, and financial analysts.
http://investor.endocyte.com/
The Investor Relations website contains information about Endocyte, Inc.'s business for stockholders, potential investors, and financial analysts.
http://investor.endocyte.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
5.8 seconds
16x16
PAGES IN
THIS WEBSITE
18
SSL
EXTERNAL LINKS
80
SITE IP
23.55.218.214
LOAD TIME
5.791 sec
SCORE
6.2
Investor Relations | Endocyte, Inc. | investor.endocyte.com Reviews
https://investor.endocyte.com
The Investor Relations website contains information about Endocyte, Inc.'s business for stockholders, potential investors, and financial analysts.
investor.endocyte.com
Email Alert Subscription - Endocyte, Inc.
http://investor.endocyte.com/profile.cfm
EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investors & News. Events & Presentations. Annual Reports and Proxies. Step 1 of 3: Select Options. You may automatically receive Endocyte, Inc. financial information by email. Please enter your preferences for email notifications below and click "Continue" to enter your contact information on the next page. If you have already signed up and would like to review your subscription, click here. Quarterly and Annual Reports.
Press Releases - Endocyte, Inc.
http://investor.endocyte.com/releases.cfm
EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investors & News. Events & Presentations. Annual Reports and Proxies. Aug 15, 2016. Endocyte Announces Presentations at the 252nd American Chemical Society National Meeting and Exposition. Aug 9, 2016. Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference. Aug 4, 2016. Endocyte Reports Second Quarter 2016 Financial Results. Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 - - Initiat...
Financials & Filings - Endocyte, Inc.
http://investor.endocyte.com/financials.cfm
EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investors & News. Events & Presentations. Annual Reports and Proxies. First Quarter 2016 Financial Results. Endocyte Reports First Quarter 2016 Financial Results. Mar 23, 2016. Apr 2, 2015. Mar 8, 2016. Mar 13, 2015. Aug 5, 2016. May 6, 2016. Add PDF file to Briefcase. Investors & News.
Stock Information - Endocyte, Inc.
http://investor.endocyte.com/stockquote.cfm
EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investors & News. Events & Presentations. Annual Reports and Proxies. 12:44 PM ET on Aug 24, 2016. Sign up for email alerts. Investors & News.
Events & Presentations - Endocyte, Inc.
http://investor.endocyte.com/events.cfm
EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investors & News. Events & Presentations. Annual Reports and Proxies. Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. 2016 ACS Poaster CBIs and conjugates. 2016 ACS Poster Design and synthesis of Small Molecule Drug Conjugates. 2016 ACS Poster MMAE. 2016 ACS Poster proPBD Hydrids. 2016 ACS Poster Somatostatin. Aug 16, 2016. Wedbush Pacgrow Healthcare Conference.
TOTAL PAGES IN THIS WEBSITE
18
Endocyte Glossary
http://endocyte.com/glossary
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. The foundational elements of our technology. Built using the same modular structure and targeting ligand as its matching small molecule drug conjugate (SMDC), it carries a small amount of radioactive material that can be seen with nuclear imaging. The therapeutic agent carried by the SMDC and designed to be precisely delivered within the diseased cell.
Endocyte Vision & Values – Targeted Drug Delivery
http://endocyte.com/about/vision
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. Vision & Values. Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:. Non-small cell lung cancer. Seeking precision in medicine for better patient outcomes. Our vision is to make precision medicine available to physicians and patients for the treatment of cancers and other difficult-to-treat diseases.
Endocyte Management
http://endocyte.com/about/management
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. Vision & Values. Working to make the promise of precision medicine a reality. Mike A. Sherman. Philip S. Low, PhD. Alison Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR. Michael A. Brinkley. Vice President, Quality. Vice President, Marketing and Communications. Scot L. Harper, PhD. Vice President, Clinical Operations. Christopher P. Leamon, PhD.
Endocyte Board of Directors
http://endocyte.com/about/board
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. Vision & Values. Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:. Non-small cell lung cancer. Watch our technology at work. Guiding the growth of Endocyte. John C. Aplin, PhD. Keith E. Brauer. Former VP Finance/Chief Financial Officer. Colin Goddard, PhD. Chairman and Chief Executive Officer. Ann F Hanham, PhD.
Endocyte EC0652 - Prostate Cancer Treatment
http://endocyte.com/pipeline/prostate-cancer-treatment
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. EC0652 Prostate Cancer Molecular Imaging*. Designed to non-invasively identify tumors that express prostate-specific membrane antigen (PSMA) receptors. Investors & News.
Endocyte Pipeline —Vintafolide
http://endocyte.com/pipeline/vintafolide
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Designed to target the folate receptor to deliver potent chemotherapy. Non-small cell lung cancer:. Vynfinit is being investigated in a Phase 1 study in patients with advanced cancers. Endocyte i...
Endocyte Discovery Stage Agents
http://endocyte.com/pipeline/discovery-agents
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Further along the path of precision medicine. EC1669 is a new approach to inflammation therapy, targeting a highly potent anti-folate drug to activated macrophages expressing folate receptors.
Endocyte Career Benefits
http://endocyte.com/careers/benefits
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. We respect and value our employees. Endocyte recognizes that employees are instrumental to our success. An environment in which employees can put their unique talents and capabilities to work is essential. Our commitment to our employees and their families is demonstrated in our competitive compensation and benefits programs. FSA for health and dependent care.
Endocyte EC1456—Chemotherapy Drug
http://endocyte.com/pipeline/chemotherapy-drug
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Designed to deliver a highly potent chemotherapy drug to folate-receptor-positive cancers. EC1456 is being co-developed with Folcepri (etarfolatide) as its companion imaging agent.
About Endocyte—Precision in Medicine
http://endocyte.com/about
Vision & Values. EC0652 Prostate Cancer Molecular Imaging. Folcepri (Etarfolatide) Molecular Imaging. Investors & News. Events & Presentations. Vision & Values. Watch our technology at work. Endocyte strives for precision in medicine. Addressing these challenges through precision medicine has been our mission since the very beginning. Physicians aspire to treat patients with precision medicine, and Endocyte is committed to giving them the tools to do it. Our process matches the biology of a diseased cell...
TOTAL LINKS TO THIS WEBSITE
80
Copec Investor
US$ 1,575.00/T.M.B. 1Q15 Results and Conference Call Invitation available. Empresas Copec nominated for ALAS20 2015. 4Q14 Results and Conference Call. Environmental Impact Statement for Arauco’s dissolving pulp project obtained unanimous approval. Terpel makes successful bond placement of COP$400 billion. Empresas Copec S.A. completes a successful bond issue. Information regarding Empresas Copec 1Q15 Earnings Release and Conference Call. Itau Andean Conference - 08:00 AM. Itau Andean Conference - 08:00 AM.
Information from Envision Healthcare |
Investing in Your Success. Quote delayed by a minimum of 15 minutes. EmCare Review of Cooper Working Paper. Envision Healthcare Completes Divestiture of American Medical Response. 2017 Annual Meeting Materials. Investing in Your Success.
Matas A/S - Investor Relations
Interim report for the period 1 April 2015 to 30 June 2015. Aug 28, 2015. Matas will host a conference call for investors and analysts, Friday 28 August at 10.30 CET. The conference call and presentation will be available via Matas’ investor website: investor.matas.dk. Conference call access numbers for investors and analysts:. DK: 45 38 48 75 13. UK: 44 (0)20 3427 1908. US: 1 646 254 3364. Please dial in 5-10 minutes prior to the start time using the number / Conference ID below. View all ». Jul 31, 2015.
PANDORA - Investor Relations
Vice President, Head of Investor Relations. LOUISE GYLLING JØRGENSEN. Transactions in connection with share buyback programme. Transactions in connection with share buyback programme. Silent period Q1 2018. Interim Report for the first quarter 2018. Conference: HSBC Luxury Goods Conference - Paris. Conference: Deutsche Bank Global Consumer Conference - Paris.
investor.en.vostoknewventures.com
Vostok New Ventures Ltd. - Investor Relations
Vostok New Ventures Ltd. The Swedish Depository Receipts (SDRs) of Vostok New Ventures Ltd (formerly Vostok Nafta Investment Ltd) are listed on Nasdaq Stockholm, Mid Cap segment, with the ticker VNV SDB. View all ». Aug 12, 2015. Vostok New Ventures to release six Months Report 2015 Wednesday, August 19, 2015. Jul 30, 2015. Avito trading statement second quarter 2015. View all ». Featured Reports and Events. Interim report for the first three months 2015. May 20, 2015. May 20, 2015. Mar 31, 2015.
Investor Relations | Endocyte, Inc.
Skip to main navigation. EC0652 Prostate Cancer Molecular Imaging. Etarfolatide (EC20) Molecular Imaging. Investor relation header menu. Annual Reports and Proxies. More information is coming soon. Mar 15, 2018. Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018. Mar 15, 2018. Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments. Mar 12, 2018 at 2:50 PM EDT. Feb 26, 2018 at 8:30 AM EST. Endocyte...
Investor Relations - Endologix
News & Events. Mar 20, 2018 at 8:30 AM ET. ENCORE Study Investor Conference Call. 015 ( 3.68%). 4:00 PM ET on Mar 29, 2018. Delayed at least 20 minutes. ENCORE Study Investor Conference Call. Mar 20, 2018 at 8:30 AM ET. Encore Ovation Analysis Presentation. File is in Briefcase. LEOPARD Trial Presentation – VEITH 2017. Nellix EVAS FORWARD IDE Data. LUCY Study 30-day Data Reveal. ASCEND Registry Presentation - Charing Cross 2016. Global Registry Podium Charing Cross 2016. Mar 19, 2018. Mar 5, 2018. The Ne...
Home
Dividend Reinvestment Plan (DRIP). View our annual report here. Code of Business Conduct. Code of Business Conduct. Our Code of Conduct. Code of Business Conduct. Our Code of Conduct. Read our Code of Business conduct and other policies. Code of Business Conduct. Our Code of Conduct. Làm website bán hàng. Code of Business Conduct. Our Code of Conduct. Why Invest in Enercare. Enercare in the News. At-a-glance information for investors. Upcoming or recent news and events about our company. Greater Toronto ...
Energomontaż-Południe SA
Nieruchomość inwestycyjna w Będzinie na sprzedaż w dniach 7 26 marca 2018 r. Przetarg na sprzedaż mieszkań w Katowicach i Tychach w dniach 7 21 lutego 2018 r. Montaż części ciśnieniowej na nowo budowanej Elektrowni Maasvlakte Power Plant w Holandii. Pakiet-1: montaż części ciśnieniowej obejmującej: montaż stropu kotła, montaż ścian pionowych od poziomu 72 m do poziomu 108 m, montaż wężownic przegrzewacza części środkowej kotła. Pakiet-2: montaż rur łączących przegrzewacze z komorami zewnętrznymi. Montaż ...
Investor Relations | EnerNOC, Inc.
Skip to main content. How You Buy It. How Much You Use. When You Use It. Who We Work With. How You Buy It. How Much You Use. When You Use It. WHO WE WORK WITH. How You Buy It. How Much You Use. When You Use It. Who We Work With. Aug 7, 2015 at 4:00 PM ET. Intraday data provided by eSignal. EnerNOC, Inc. (NASDAQ: ENOC. Press Releases View all. Aug 6, 2015. EnerNOC Reports Results for Second Quarter of 2015. Jul 28, 2015. EnerNOC to Present at Upcoming Investor Conferences. Events and Presentations View all.
Investor Relations | Enphase Energy
Enphase Energy delivers energy management technology for the solar industry that increases energy production, simplifies design and installation, improves system uptime and reliability, reduces fire safety risk and provides a platform for intelligent energy management. Its semiconductor-based microinverter system converts energy at the individual solar module level and brings a system-based high-technology approach to solar energy generation, storage, control and management. Day High: 4.83. Mar 29, 2018.
SOCIAL ENGAGEMENT